首页 > 最新文献

Journal of interventional cardiology最新文献

英文 中文
A Comparative Analysis of Primary and Bailout ADR in CTO-PCI CTO-PCI 中初级 ADR 与救助 ADR 的比较分析
IF 1.6 3区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-11-04 DOI: 10.1155/2024/4501880
Lirui Yang, Tao Zhang, Gang Wang, Leisheng Ru, Lin Zhao

Objective: To compare the efficiency and safety of primary and bailout antegrade dissection and re-entry (ADR) during percutaneous coronary intervention (PCI) for chronic total occluded (CTO) lesions.

Methods: Patients who underwent ADR procedures for CTO lesions were enrolled in this study and were divided into two groups (primary ADR and bailout ADR) based on the initiation of ADR during PCI. The success rate and major adverse cardiovascular and cerebrovascular events (MACCE) during hospitalization were assessed as the primary endpoints. Procedure time, fluoroscopy time, wire crossing time, radiation dose, and contrast volume were considered as secondary endpoints.

Results: A total of 243 patients were enrolled in this study, with 127 patients receiving primary ADR and 116 receiving bailout ADR. No differences were found in baseline parameters between the two groups. The success rate was significantly higher in the primary ADR group compared to the bailout ADR group (89.0% versus 77.6%, respectively; p = 0.017). The incidence of in-hospital MACCE was low in both groups, with no significant differences observed between them. Procedure time, radiation dose, and contrast volume were lower in the primary ADR group compared to the bailout ADR group. Cox regression analysis revealed that primary ADR and J-CTO score ≥ 3 were independent predictors of technical success in CTO-PCI.

Conclusions: Both primary and bailout ADR are safe strategies for CTO-PCI. Primary ADR significantly improves the success rate of PCI for CTO compared to bailout ADR, with shorter operation time, lower radiation dose, and reduced contrast volume.

目的比较慢性全闭塞(CTO)病变经皮冠状动脉介入治疗(PCI)过程中,原发性和救助性前向夹层和再入路(ADR)的效率和安全性。 方法:本研究纳入了接受 ADR 手术治疗 CTO 病变的患者,并根据 PCI 期间启动 ADR 的情况将其分为两组(主要 ADR 组和救助 ADR 组)。成功率和住院期间的主要心脑血管不良事件(MACCE)作为主要终点进行评估。手术时间、透视时间、导线穿越时间、辐射剂量和造影剂用量被视为次要终点。 结果:共有 243 名患者参与了这项研究,其中 127 名患者接受了主要 ADR,116 名患者接受了备用 ADR。两组患者的基线参数无差异。初级 ADR 组的成功率明显高于救助 ADR 组(分别为 89.0% 对 77.6%;P = 0.017)。两组的院内 MACCE 发生率均较低,无明显差异。与保外 ADR 组相比,原发性 ADR 组的手术时间、放射剂量和造影剂用量更少。Cox 回归分析显示,原发性 ADR 和 J-CTO 评分≥3 是 CTO-PCI 技术成功的独立预测因素。 结论:初级 ADR 和保外 ADR 都是 CTO-PCI 的安全策略。与保外ADR相比,原发性ADR能明显提高CTO PCI的成功率,手术时间更短、辐射剂量更低、造影剂用量更少。
{"title":"A Comparative Analysis of Primary and Bailout ADR in CTO-PCI","authors":"Lirui Yang,&nbsp;Tao Zhang,&nbsp;Gang Wang,&nbsp;Leisheng Ru,&nbsp;Lin Zhao","doi":"10.1155/2024/4501880","DOIUrl":"https://doi.org/10.1155/2024/4501880","url":null,"abstract":"<div>\u0000 <p><b>Objective:</b> To compare the efficiency and safety of primary and bailout antegrade dissection and re-entry (ADR) during percutaneous coronary intervention (PCI) for chronic total occluded (CTO) lesions.</p>\u0000 <p><b>Methods:</b> Patients who underwent ADR procedures for CTO lesions were enrolled in this study and were divided into two groups (primary ADR and bailout ADR) based on the initiation of ADR during PCI. The success rate and major adverse cardiovascular and cerebrovascular events (MACCE) during hospitalization were assessed as the primary endpoints. Procedure time, fluoroscopy time, wire crossing time, radiation dose, and contrast volume were considered as secondary endpoints.</p>\u0000 <p><b>Results:</b> A total of 243 patients were enrolled in this study, with 127 patients receiving primary ADR and 116 receiving bailout ADR. No differences were found in baseline parameters between the two groups. The success rate was significantly higher in the primary ADR group compared to the bailout ADR group (89.0% versus 77.6%, respectively; <i>p</i> = 0.017). The incidence of in-hospital MACCE was low in both groups, with no significant differences observed between them. Procedure time, radiation dose, and contrast volume were lower in the primary ADR group compared to the bailout ADR group. Cox regression analysis revealed that primary ADR and J-CTO score ≥ 3 were independent predictors of technical success in CTO-PCI.</p>\u0000 <p><b>Conclusions:</b> Both primary and bailout ADR are safe strategies for CTO-PCI. Primary ADR significantly improves the success rate of PCI for CTO compared to bailout ADR, with shorter operation time, lower radiation dose, and reduced contrast volume.</p>\u0000 </div>","PeriodicalId":16329,"journal":{"name":"Journal of interventional cardiology","volume":"2024 1","pages":""},"PeriodicalIF":1.6,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/4501880","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142579615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Effect of Electromagnetic Interference Produced by Smartphones Using 5G Network on Patients With Permanent Pacemakers (EMS5G-PPM Study) 使用 5G 网络的智能手机产生的电磁干扰对永久起搏器患者的影响(EMS5G-PPM 研究)
IF 1.6 3区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-27 DOI: 10.1155/2024/3550004
Treechada Wisaratapong, Nutthapong Pechaksorn, Tippawan Liabsuetrakul, Watchara Lohawijarn

Background: The safety of new-generation mobile phones using 5G networks in patients with modern-generation pacemakers has not been studied.

Objectives: This study aimed to compare the risk of electromagnetic interference (EMI) generated by a new-generation mobile phone with 5G networks when positioned at the pacemaker pocket or the contralateral ear and assess the incidence of EMI with telemetry interrogation in patients with permanent pacemakers.

Methods: We enrolled 489 patients with pacemakers from three different manufacturers. The pacemaker mode was programmed for overdrive pacing and sensing mode if an intrinsic rhythm was present. A smartphone (Samsung S21 + 5G) was placed directly over the pulse generator and right ear. The phone was tested under standby mode, 5G internet connection, and incoming and outgoing calls for each location. Real-time electrocardiography (ECG) monitoring and patient symptoms were recorded to determine the occurrence of EMI. The possibility of EMI with interrogation telemetry was also investigated.

Results: A total of 4824 tests were performed on 489 patients. Most pacemakers were dual-chamber (82%) or magnetic resonance imaging (MRI)-compatible systems (83%). EMI was not detected with both mobile phone positions. Interference with telemetry was demonstrated in 11.5% of patients. Almost all incidences of interference (98.2%) occurred during incoming calls. Single-chamber pacemakers, non-MRI-compatible systems, older pulse generators, older leads, and unipolar settings were significantly related to a higher incidence of interference with interrogation telemetry.

Conclusions: The risk of EMI between modern smartphones with 5G networks and pacemakers is low. Nevertheless, interference with the interrogation telemetry may still occur.

背景:使用 5G 网络的新一代移动电话对现代心脏起搏器患者的安全性尚未进行研究。 研究目的本研究旨在比较使用 5G 网络的新一代移动电话放置在心脏起搏器袋或对侧耳时产生电磁干扰(EMI)的风险,并评估永久性心脏起搏器患者在接受遥测询问时 EMI 的发生率。 研究方法我们招募了 489 名使用三个不同制造商生产的起搏器的患者。起搏器模式设定为超速起搏,如果存在内在节律,则设定为传感模式。一部智能手机(三星 S21 + 5G)被直接放置在脉冲发生器和右耳上方。手机在待机模式、5G 互联网连接以及每个位置的来电和去电情况下进行测试。对实时心电图(ECG)监测和患者症状进行了记录,以确定是否发生了 EMI。此外,还调查了讯问遥测发生 EMI 的可能性。 结果:共对 489 名患者进行了 4824 次测试。大多数起搏器为双腔(82%)或磁共振成像(MRI)兼容系统(83%)。两种手机位置均未检测到电磁干扰。11.5% 的患者出现了遥测干扰。几乎所有干扰事件(98.2%)都发生在来电时。单腔起搏器、非 MRI 兼容系统、较旧的脉冲发生器、较旧的导联和单极设置与较高的遥测干扰发生率明显相关。 结论使用 5G 网络的现代智能手机与心脏起搏器之间的电磁干扰风险很低。不过,干扰询问遥测的情况仍有可能发生。
{"title":"The Effect of Electromagnetic Interference Produced by Smartphones Using 5G Network on Patients With Permanent Pacemakers (EMS5G-PPM Study)","authors":"Treechada Wisaratapong,&nbsp;Nutthapong Pechaksorn,&nbsp;Tippawan Liabsuetrakul,&nbsp;Watchara Lohawijarn","doi":"10.1155/2024/3550004","DOIUrl":"https://doi.org/10.1155/2024/3550004","url":null,"abstract":"<div>\u0000 <p><b>Background:</b> The safety of new-generation mobile phones using 5G networks in patients with modern-generation pacemakers has not been studied.</p>\u0000 <p><b>Objectives:</b> This study aimed to compare the risk of electromagnetic interference (EMI) generated by a new-generation mobile phone with 5G networks when positioned at the pacemaker pocket or the contralateral ear and assess the incidence of EMI with telemetry interrogation in patients with permanent pacemakers.</p>\u0000 <p><b>Methods:</b> We enrolled 489 patients with pacemakers from three different manufacturers. The pacemaker mode was programmed for overdrive pacing and sensing mode if an intrinsic rhythm was present. A smartphone (Samsung S21 + 5G) was placed directly over the pulse generator and right ear. The phone was tested under standby mode, 5G internet connection, and incoming and outgoing calls for each location. Real-time electrocardiography (ECG) monitoring and patient symptoms were recorded to determine the occurrence of EMI. The possibility of EMI with interrogation telemetry was also investigated.</p>\u0000 <p><b>Results:</b> A total of 4824 tests were performed on 489 patients. Most pacemakers were dual-chamber (82%) or magnetic resonance imaging (MRI)-compatible systems (83%). EMI was not detected with both mobile phone positions. Interference with telemetry was demonstrated in 11.5% of patients. Almost all incidences of interference (98.2%) occurred during incoming calls. Single-chamber pacemakers, non-MRI-compatible systems, older pulse generators, older leads, and unipolar settings were significantly related to a higher incidence of interference with interrogation telemetry.</p>\u0000 <p><b>Conclusions:</b> The risk of EMI between modern smartphones with 5G networks and pacemakers is low. Nevertheless, interference with the interrogation telemetry may still occur.</p>\u0000 </div>","PeriodicalId":16329,"journal":{"name":"Journal of interventional cardiology","volume":"2024 1","pages":""},"PeriodicalIF":1.6,"publicationDate":"2024-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/3550004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142525418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of Sheathless and Sheathed Guiding Catheters in Transradial Percutaneous Coronary Interventions: A Systematic Review and Meta-Analysis 经桡动脉经皮冠状动脉介入治疗中无鞘和有鞘导引导管的比较:系统回顾与元分析
IF 1.6 3区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-23 DOI: 10.1155/2024/2777585
Zuhair Majeed, Muhammad Haider Tariq, Arslan Ahmed, Muhammad Usama, Ahmed Mazen Amin, Abira Khan, Muhammad Shahzaib Bajwa, Muhammad Faiq Umar, Mustafa Turkmani, Mohamed Abuelazm, Ubaid Khan

Introduction: The sheathless transradial (TR) technique is a novel approach that may offer potential benefits over the conventional TR approach. We aim to comprehensively investigate the safety and efficacy of sheathless versus conventional TR percutaneous coronary interventions (PCIs).

Methods: We conducted comprehensive searches across PubMed, CENTRAL, Web of Science (WOS), Scopus, and EMBASE until July 2023. Pooled data were reported using risk ratio (RR) for dichotomous outcomes and mean difference (MD) for continuous outcomes, along with a 95% confidence interval (CI). PROSPERO ID: CRD42023443834.

Results: We included 11 studies with 15,392 patients. The radial artery spasm (RAS) (RR: 0.26, 95% CI: [0.09, 0.77], p = 0.02) and cross-over to the femoral site (RR: 0.28, 95% CI: [0.10, 0.81], p = 0.02) were significantly lower in the sheathless group. However, radial artery occlusion (RAO) (RR: 2.84, 95% CI: [1.78, 4.54], p < 0.0001) and success rate (RR: 1.011, 95% CI: [1.004, 1.019], p = 0.002) were significantly higher in the sheathless group. Also, we did not find a significant difference between both groups in all-cause mortality (RR: 0.41, 95% CI: [0.16, 1.04], p = 0.06).

Conclusion: The sheathless TR approach showed lower rates of RAS and femoral conversion. Sheathless has a higher success rate; however, it also increased RAO. Thus, more trials are needed to confirm this technique’s long-term outcomes and complications.

简介:无鞘经桡动脉(TR)技术是一种新型方法,与传统的TR方法相比具有潜在优势。我们旨在全面研究无鞘经皮冠状动脉介入治疗(PCI)与传统经皮冠状动脉介入治疗(TR)的安全性和有效性。 方法:截至 2023 年 7 月,我们在 PubMed、CENTRAL、Web of Science (WOS)、Scopus 和 EMBASE 中进行了全面检索。对于二分结果,我们使用风险比 (RR) 报告汇总数据;对于连续结果,我们使用平均差 (MD) 报告汇总数据,并给出 95% 的置信区间 (CI)。PROSPERO ID:CRD42023443834。 结果:我们纳入了 11 项研究,共 15,392 名患者。无鞘组的桡动脉痉挛(RAS)(RR:0.26,95% CI:[0.09,0.77],P = 0.02)和股动脉部位交叉(RR:0.28,95% CI:[0.10,0.81],P = 0.02)显著低于无鞘组。然而,无鞘组的桡动脉闭塞(RAO)(RR:2.84,95% CI:[1.78,4.54],p = 0.0001)和成功率(RR:1.011,95% CI:[1.004,1.019],p = 0.002)明显更高。此外,我们没有发现两组在全因死亡率上有明显差异(RR:0.41,95% CI:[0.16,1.04],P = 0.06)。 结论无鞘 TR 方法的 RAS 和股骨转换率较低。无鞘的成功率更高,但也增加了RAO。因此,需要更多的试验来证实这种技术的长期效果和并发症。
{"title":"Comparison of Sheathless and Sheathed Guiding Catheters in Transradial Percutaneous Coronary Interventions: A Systematic Review and Meta-Analysis","authors":"Zuhair Majeed,&nbsp;Muhammad Haider Tariq,&nbsp;Arslan Ahmed,&nbsp;Muhammad Usama,&nbsp;Ahmed Mazen Amin,&nbsp;Abira Khan,&nbsp;Muhammad Shahzaib Bajwa,&nbsp;Muhammad Faiq Umar,&nbsp;Mustafa Turkmani,&nbsp;Mohamed Abuelazm,&nbsp;Ubaid Khan","doi":"10.1155/2024/2777585","DOIUrl":"https://doi.org/10.1155/2024/2777585","url":null,"abstract":"<div>\u0000 <p><b>Introduction:</b> The sheathless transradial (TR) technique is a novel approach that may offer potential benefits over the conventional TR approach. We aim to comprehensively investigate the safety and efficacy of sheathless versus conventional TR percutaneous coronary interventions (PCIs).</p>\u0000 <p><b>Methods:</b> We conducted comprehensive searches across PubMed, CENTRAL, Web of Science (WOS), Scopus, and EMBASE until July 2023. Pooled data were reported using risk ratio (RR) for dichotomous outcomes and mean difference (MD) for continuous outcomes, along with a 95% confidence interval (CI). PROSPERO ID: CRD42023443834.</p>\u0000 <p><b>Results:</b> We included 11 studies with 15,392 patients. The radial artery spasm (RAS) (RR: 0.26, 95% CI: [0.09, 0.77], <i>p</i> = 0.02) and cross-over to the femoral site (RR: 0.28, 95% CI: [0.10, 0.81], <i>p</i> = 0.02) were significantly lower in the sheathless group. However, radial artery occlusion (RAO) (RR: 2.84, 95% CI: [1.78, 4.54], <i>p</i> &lt; 0.0001) and success rate (RR: 1.011, 95% CI: [1.004, 1.019], <i>p</i> = 0.002) were significantly higher in the sheathless group. Also, we did not find a significant difference between both groups in all-cause mortality (RR: 0.41, 95% CI: [0.16, 1.04], <i>p</i> = 0.06).</p>\u0000 <p><b>Conclusion:</b> The sheathless TR approach showed lower rates of RAS and femoral conversion. Sheathless has a higher success rate; however, it also increased RAO. Thus, more trials are needed to confirm this technique’s long-term outcomes and complications.</p>\u0000 </div>","PeriodicalId":16329,"journal":{"name":"Journal of interventional cardiology","volume":"2024 1","pages":""},"PeriodicalIF":1.6,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/2777585","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142525111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Percutaneous Coronary Intervention Using the DynamX Sirolimus-Eluting Bioadaptor: 12-Month Clinical and Imaging Outcomes 使用 DynamX Sirolimus 洗脱生物适配器进行经皮冠状动脉介入治疗:12 个月的临床和成像结果
IF 1.6 3区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-17 DOI: 10.1155/2024/8876443
Mark Webster, Douglas Scott, Madhav Menon, Dougal McClean, Seif El-Jack, Gerard Wilkins, Scott A. Harding

The DynamX Bioadaptor is a novel implant with uncaging elements that disengage after polymer resorption and permits restoration of vessel function, thereby potentially reducing late adverse cardiac events. We evaluated the safety and efficacy of this novel implant with imaging follow-up at 6-months, the time point when the bioadaptor starts to uncage. This prospective study enrolled 44 patients with up to two de novo lesions at seven centers in New Zealand treated with the DynamX Bioadaptor. Follow-up was planned out to 12-months. The primary safety and efficacy endpoints were 6-month target lesion failure (TLF) and late lumen loss. Patients presented with non-ST elevation myocardial infarction in 49%. Lesions (n = 45) were 16.0 ± 6.7 mm long, and 2.81 ± 0.41 mm in diameter. Device and procedure success were 100%, and acute lumen gain was 1.93 ± 0.35 mm. At 6-months, median in-device late lumen loss was 0.09 mm (IQR:0.05–0.16). Measured by intravascular ultrasound, the vessel, lumen, and device area remained constant. By optical coherence tomography, 96.4% ± 5.9% of struts per lesion were covered. Out to 12-months, no TLF and no definite or probable device thrombosis were reported. In conclusion, this study provides evidence of the safety and performance of the DynamX Bioadaptor with excellent 12-month clinical and 6-month imaging outcomes comparable to best-in-class drug-eluting stents (DES).

Trial Registration: ClinicalTrials.gov identifier: NCT03634020, NCT05464147, NCT04562805, and NCT04192747.

DynamX 生物适配器是一种新型植入物,它具有可在聚合物吸收后脱离的解笼元件,允许恢复血管功能,从而可能减少后期不良心脏事件。我们对这种新型植入物的安全性和有效性进行了评估,并在生物适配器开始松开的 6 个月后进行了成像随访。这项前瞻性研究在新西兰的 7 个中心招募了 44 名接受 DynamX 生物适配器治疗的患者,这些患者最多有两个新发病灶。计划随访 12 个月。主要的安全性和有效性终点是6个月靶病变失败(TLF)和晚期管腔缺损。49%的患者出现非ST段抬高型心肌梗死。病变(n = 45)长度为 16.0 ± 6.7 毫米,直径为 2.81 ± 0.41 毫米。设备和手术成功率均为 100%,急性管腔增宽为 1.93 ± 0.35 毫米。6个月后,装置内晚期管腔损失的中位数为0.09毫米(IQR:0.05-0.16)。通过血管内超声测量,血管、管腔和装置面积保持不变。通过光学相干断层扫描,每个病变的支架覆盖率为 96.4% ± 5.9%。术后 12 个月内,无 TLF 报告,无明确或可能的装置血栓形成。总之,这项研究证明了 DynamX Bioadaptor 的安全性和性能,其 12 个月的临床和 6 个月的成像结果与同类最佳药物洗脱支架 (DES) 不相上下。 试验注册:临床试验注册:ClinicalTrials.gov identifier:NCT03634020、NCT05464147、NCT04562805 和 NCT04192747。
{"title":"Percutaneous Coronary Intervention Using the DynamX Sirolimus-Eluting Bioadaptor: 12-Month Clinical and Imaging Outcomes","authors":"Mark Webster,&nbsp;Douglas Scott,&nbsp;Madhav Menon,&nbsp;Dougal McClean,&nbsp;Seif El-Jack,&nbsp;Gerard Wilkins,&nbsp;Scott A. Harding","doi":"10.1155/2024/8876443","DOIUrl":"https://doi.org/10.1155/2024/8876443","url":null,"abstract":"<div>\u0000 <p>The DynamX Bioadaptor is a novel implant with uncaging elements that disengage after polymer resorption and permits restoration of vessel function, thereby potentially reducing late adverse cardiac events. We evaluated the safety and efficacy of this novel implant with imaging follow-up at 6-months, the time point when the bioadaptor starts to uncage. This prospective study enrolled 44 patients with up to two de novo lesions at seven centers in New Zealand treated with the DynamX Bioadaptor. Follow-up was planned out to 12-months. The primary safety and efficacy endpoints were 6-month target lesion failure (TLF) and late lumen loss. Patients presented with non-ST elevation myocardial infarction in 49%. Lesions (<i>n</i> = 45) were 16.0 ± 6.7 mm long, and 2.81 ± 0.41 mm in diameter. Device and procedure success were 100%, and acute lumen gain was 1.93 ± 0.35 mm. At 6-months, median in-device late lumen loss was 0.09 mm (IQR:0.05–0.16). Measured by intravascular ultrasound, the vessel, lumen, and device area remained constant. By optical coherence tomography, 96.4% ± 5.9% of struts per lesion were covered. Out to 12-months, no TLF and no definite or probable device thrombosis were reported. In conclusion, this study provides evidence of the safety and performance of the DynamX Bioadaptor with excellent 12-month clinical and 6-month imaging outcomes comparable to best-in-class drug-eluting stents (DES).</p>\u0000 <p><b>Trial Registration:</b> ClinicalTrials.gov identifier: NCT03634020, NCT05464147, NCT04562805, and NCT04192747.</p>\u0000 </div>","PeriodicalId":16329,"journal":{"name":"Journal of interventional cardiology","volume":"2024 1","pages":""},"PeriodicalIF":1.6,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/8876443","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142447743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vascular Complications and Bleeding After Transfemoral TAVR With Surgical Versus Percutaneous Approach: A Contemporary Prospective Study 手术与经皮途径经股动脉 TAVR 术后的血管并发症和出血:一项当代前瞻性研究
IF 1.6 3区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-14 DOI: 10.1155/2024/8355054
Annick Astié Dardaillon, Mariama Akodad, Fabien Huet, Pierre Alain Meunier, Thomas Gandet, Jean-Christophe Macia, Laurent Schmutz, Frederic Targosz, François Roubille, Matthieu Steinecker, Benoit Lattuca, Pierre Robert, Jean-Michel Berdeu, Guillaume Cayla, Florence Leclercq

Background: Percutaneous (PC) access has become the first-line strategy for transfemoral (TF) transcatheter aortic valve replacement (TAVR), but surgical cutdown (SC) may be required in selected and usually challenging cases. We aimed to compare the efficacy and safety of SC versus echo-guided PC approach in TF TAVR.

Methods: Between November 2019 and December 2020, all patients undergoing TF TAVR were included in a prospective study. The choice of PC or SC strategy was left at operators’ discretion, according to predictable access site difficulties. The primary endpoint included all vascular complications (VCs) and all bleeding at 1-month follow-up according to Valve Academic Research Consortium-2 criteria.

Results: Among 225 patients, 166 (73.8%) and 59 (26.2%) underwent PC or SC approach, respectively. Median age was 82 years, EuroSCORE 2 was higher (p = 0.02), and peripheral arterial disease (p < 0.001) was more common in the SC group. Femoral access was successful in 100% in the SC group vs 97.6% in the PC group (p = 0.2). The primary endpoint was reached in 32 patients (14.2%), 5 (8.4%) in the SC group and 27 (16.2%) in the PC group (p = 0.1) with low incidence of major VC in both groups (1.7% vs 3% in the SC and PC groups respectively, p = 0.6).

Conclusion: Despite a higher risk profile of patients in the SC group, SC and PC approaches appear safe and effective in TF TAVR, with a high success rate. SC may be considered when vascular access is anticipated as complex, but this strategy might be confirmed in a randomized study.

Trial Registration: ClinicalTrials.gov identifier: NCT03865043

背景:经皮(PC)入路已成为经股动脉(TF)主动脉瓣置换术(TAVR)的一线策略,但在某些通常具有挑战性的病例中可能需要手术切开(SC)。我们旨在比较 SC 与回声引导 PC 入路在 TF TAVR 中的有效性和安全性。 方法:在 2019 年 11 月至 2020 年 12 月期间,所有接受 TF TAVR 的患者都纳入了一项前瞻性研究。根据可预测的入路部位困难,由操作者自行决定选择 PC 或 SC 策略。根据瓣膜学术研究联盟-2标准,主要终点包括随访1个月时的所有血管并发症(VC)和所有出血。 结果:在 225 名患者中,分别有 166 人(73.8%)和 59 人(26.2%)采用 PC 或 SC 方法。SC组的中位年龄为82岁,EuroSCORE 2更高(p = 0.02),外周动脉疾病更常见(p < 0.001)。股骨入路成功率 SC 组为 100%,PC 组为 97.6%(p = 0.2)。有 32 名患者(14.2%)达到了主要终点,SC 组有 5 名(8.4%),PC 组有 27 名(16.2%)(P = 0.1),两组的主要 VC 发生率都很低(SC 组和 PC 组分别为 1.7% 和 3%,P = 0.6)。 结论尽管SC组患者风险较高,但SC和PC方法在TF TAVR中似乎安全有效,成功率较高。当预计血管通路较为复杂时,可考虑使用 SC,但这一策略可能需要在随机研究中得到证实。 试验注册:ClinicalTrials.gov 标识符:NCT03865043
{"title":"Vascular Complications and Bleeding After Transfemoral TAVR With Surgical Versus Percutaneous Approach: A Contemporary Prospective Study","authors":"Annick Astié Dardaillon,&nbsp;Mariama Akodad,&nbsp;Fabien Huet,&nbsp;Pierre Alain Meunier,&nbsp;Thomas Gandet,&nbsp;Jean-Christophe Macia,&nbsp;Laurent Schmutz,&nbsp;Frederic Targosz,&nbsp;François Roubille,&nbsp;Matthieu Steinecker,&nbsp;Benoit Lattuca,&nbsp;Pierre Robert,&nbsp;Jean-Michel Berdeu,&nbsp;Guillaume Cayla,&nbsp;Florence Leclercq","doi":"10.1155/2024/8355054","DOIUrl":"https://doi.org/10.1155/2024/8355054","url":null,"abstract":"<div>\u0000 <p><b>Background:</b> Percutaneous (PC) access has become the first-line strategy for transfemoral (TF) transcatheter aortic valve replacement (TAVR), but surgical cutdown (SC) may be required in selected and usually challenging cases. We aimed to compare the efficacy and safety of SC versus echo-guided PC approach in TF TAVR.</p>\u0000 <p><b>Methods:</b> Between November 2019 and December 2020, all patients undergoing TF TAVR were included in a prospective study. The choice of PC or SC strategy was left at operators’ discretion, according to predictable access site difficulties. The primary endpoint included all vascular complications (VCs) and all bleeding at 1-month follow-up according to Valve Academic Research Consortium-2 criteria.</p>\u0000 <p><b>Results:</b> Among 225 patients, 166 (73.8%) and 59 (26.2%) underwent PC or SC approach, respectively. Median age was 82 years, EuroSCORE 2 was higher (<i>p</i> = 0.02), and peripheral arterial disease (<i>p</i> &lt; 0.001) was more common in the SC group. Femoral access was successful in 100% in the SC group <i>vs</i> 97.6% in the PC group (<i>p</i> = 0.2). The primary endpoint was reached in 32 patients (14.2%), 5 (8.4%) in the SC group and 27 (16.2%) in the PC group (<i>p</i> = 0.1) with low incidence of major VC in both groups (1.7% vs 3% in the SC and PC groups respectively, <i>p</i> = 0.6).</p>\u0000 <p><b>Conclusion:</b> Despite a higher risk profile of patients in the SC group, SC and PC approaches appear safe and effective in TF TAVR, with a high success rate. SC may be considered when vascular access is anticipated as complex, but this strategy might be confirmed in a randomized study.</p>\u0000 <p><b>Trial Registration:</b> ClinicalTrials.gov identifier: NCT03865043</p>\u0000 </div>","PeriodicalId":16329,"journal":{"name":"Journal of interventional cardiology","volume":"2024 1","pages":""},"PeriodicalIF":1.6,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/8355054","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142435512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of Drug-Coated Balloons on Inflammatory Cytokines After Interventional Therapy for Coronary Artery Calcification 冠状动脉钙化介入治疗后药物涂层球囊对炎性细胞因子的影响
IF 1.6 3区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-09-24 DOI: 10.1155/2024/1082261
Jiaming Yu, Feng Zhu, Aqiang Yang, Zhi Wang, Chi Yuan, Guohua Xia, Wei Wang, Xuanwei Song, Zhengzheng Chen, Yinji Wu, Yihang Sun, Lingxiao Pan, Yongsheng Ke, Hegui Wang

Objective: To investigate the effects of a drug-coated balloon (DCB) on inflammatory cytokines in patients with coronary artery calcification (CAC) after interventional therapy.

Methods: This study included 58 patients with coronary heart disease who underwent coronary angiography (CAG) from October 2020 to September 2021. Patients were divided into CAC and non-CAC groups, and a DCB was used to intervene in the target lesions. Ten-milliliter preoperative and postoperative blood samples were drawn from the coronary lesions in both groups to detect the expression of serum interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and intercellular adhesion molecule-1 (ICAM-1). All patients were subjected to a 6-month follow-up to observe the incidence of major adverse cardiac events (MACEs).

Results: No significant differences in baseline clinical data were found between the groups. Serum IL-6, TNF-α, and ICAM-1 expressions in coronary blood samples immediately before DCB were not significantly different from those after DCB in all patients. After DCB, serum TNF-α expression in the CAC group was significantly lower than that in the non-CAC group (p < 0.05). In contrast, no significant difference in serum IL-6 and ICAM-1 expression was found between the groups. During the 6-month follow-up, no significant difference in the incidence of MACE was found between both groups.

Conclusions: DCB reduced the expression of inflammatory cytokine TNF-α in CAC, which may be one of the key mechanisms underlying the treatment of CAC by DCB.

目的研究药物涂层球囊(DCB)对冠状动脉钙化(CAC)患者介入治疗后炎症细胞因子的影响。 研究方法本研究纳入了 2020 年 10 月至 2021 年 9 月期间接受冠状动脉造影术(CAG)的 58 名冠心病患者。患者被分为 CAC 组和非 CAC 组,并使用 DCB 介入靶病变。两组患者术前和术后均从冠状动脉病变处抽取10毫升血液样本,检测血清白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)和细胞间粘附分子-1(ICAM-1)的表达。对所有患者进行为期 6 个月的随访,观察主要心脏不良事件(MACE)的发生率。 结果两组患者的基线临床数据无明显差异。所有患者冠状动脉造影术前血清IL-6、TNF-α和ICAM-1的表达与造影术后无明显差异。DCB 后,CAC 组血清 TNF-α 的表达明显低于非 CAC 组(p < 0.05)。相比之下,两组患者血清中 IL-6 和 ICAM-1 的表达没有明显差异。在 6 个月的随访中,两组患者的 MACE 发生率无明显差异。 结论DCB降低了CAC中炎症细胞因子TNF-α的表达,这可能是DCB治疗CAC的关键机制之一。
{"title":"Effects of Drug-Coated Balloons on Inflammatory Cytokines After Interventional Therapy for Coronary Artery Calcification","authors":"Jiaming Yu,&nbsp;Feng Zhu,&nbsp;Aqiang Yang,&nbsp;Zhi Wang,&nbsp;Chi Yuan,&nbsp;Guohua Xia,&nbsp;Wei Wang,&nbsp;Xuanwei Song,&nbsp;Zhengzheng Chen,&nbsp;Yinji Wu,&nbsp;Yihang Sun,&nbsp;Lingxiao Pan,&nbsp;Yongsheng Ke,&nbsp;Hegui Wang","doi":"10.1155/2024/1082261","DOIUrl":"https://doi.org/10.1155/2024/1082261","url":null,"abstract":"<div>\u0000 <p><b>Objective:</b> To investigate the effects of a drug-coated balloon (DCB) on inflammatory cytokines in patients with coronary artery calcification (CAC) after interventional therapy.</p>\u0000 <p><b>Methods:</b> This study included 58 patients with coronary heart disease who underwent coronary angiography (CAG) from October 2020 to September 2021. Patients were divided into CAC and non-CAC groups, and a DCB was used to intervene in the target lesions. Ten-milliliter preoperative and postoperative blood samples were drawn from the coronary lesions in both groups to detect the expression of serum interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-<i>α</i>), and intercellular adhesion molecule-1 (ICAM-1). All patients were subjected to a 6-month follow-up to observe the incidence of major adverse cardiac events (MACEs).</p>\u0000 <p><b>Results:</b> No significant differences in baseline clinical data were found between the groups. Serum IL-6, TNF-<i>α</i>, and ICAM-1 expressions in coronary blood samples immediately before DCB were not significantly different from those after DCB in all patients. After DCB, serum TNF-<i>α</i> expression in the CAC group was significantly lower than that in the non-CAC group (<i>p</i> &lt; 0.05). In contrast, no significant difference in serum IL-6 and ICAM-1 expression was found between the groups. During the 6-month follow-up, no significant difference in the incidence of MACE was found between both groups.</p>\u0000 <p><b>Conclusions:</b> DCB reduced the expression of inflammatory cytokine TNF-<i>α</i> in CAC, which may be one of the key mechanisms underlying the treatment of CAC by DCB.</p>\u0000 </div>","PeriodicalId":16329,"journal":{"name":"Journal of interventional cardiology","volume":"2024 1","pages":""},"PeriodicalIF":1.6,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/1082261","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142320674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chitosan-Based Hemostatic Pad Reduced Vascular Complications After Transradial Coronary Intervention in Uncontrolled Hypertensive Patients: Application of Chitosan-Based Hemostatic Pad on CAG or PCI 壳聚糖止血垫可减少未受控制的高血压患者经桡动脉冠状动脉介入术后的血管并发症壳聚糖止血垫在CAG或PCI上的应用
IF 1.6 3区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-09-17 DOI: 10.1155/2024/4819420
Lu Qian, Ming-Qiang Cao, Ze-Xiong Feng, Cao Zou, Si-Jia Sun, Sheng-Da Hu

Background: Vascular complications after coronary angiography (CAG) or percutaneous coronary intervention (PCI) are a major concern for revascularization therapies. In this study, we investigated whether the application of a chitosan-based hemostatic pad (HP) could ameliorate vascular complications after CAG or PCI procedures.

Methods: We retrospectively analyzed patients undergoing CAG or PCI in our cardiovascular center from January 2019 to December 2021. The incidence of total vascular complications including errhysis, large hematoma, pseudoaneurysm, radial artery occlusion (RAO), blister, and pain was recorded. Subgroup analyses of patients with a history of hypertension, patients with uncontrolled hypertension, and patients with controlled hypertension were performed.

Results: Our results demonstrated that the application of chitosan-based HP had no effect on vascular complications after CAG or PCI procedures (odds ratio [OR]: 1.03 (0.84–1.26), p = 0.80). Nevertheless, chitosan-based HP treatment markedly decreased the incidence of vascular complications in uncontrolled hypertensive patients (OR: 0.32 (0.11–0.95), p = 0.04), but not in hypertensive patients with controlled blood pressure (BP) (OR: 1.09 (0.88–1.35), p = 0.42).

Conclusions: Chitosan-based HP treatment could reduce the incidence of vascular complications in patients with uncontrolled hypertension. Nonetheless, applying chitosan-based HP treatment after CAG or PCI procedures is not recommendable for controlled hypertensive patients.

背景:冠状动脉造影术(CAG)或经皮冠状动脉介入治疗(PCI)后的血管并发症是血管重建疗法的主要问题。在这项研究中,我们探讨了应用壳聚糖止血垫(HP)能否改善 CAG 或 PCI 术后的血管并发症。 方法:我们回顾性分析了2019年1月至2021年12月在我们心血管中心接受CAG或PCI手术的患者。记录了包括呃逆、大血肿、假性动脉瘤、桡动脉闭塞(RAO)、水泡和疼痛在内的全部血管并发症的发生率。对有高血压病史的患者、未控制的高血压患者和已控制的高血压患者进行了分组分析。 结果结果表明,应用壳聚糖 HP 对 CAG 或 PCI 术后的血管并发症没有影响(几率比 [OR]:1.03 (0.84-1.26), p = 0.80).然而,壳聚糖 HP 治疗显著降低了未控制的高血压患者的血管并发症发生率(OR:0.32 (0.11-0.95),p = 0.04),但未降低控制血压 (BP) 的高血压患者的血管并发症发生率(OR:1.09 (0.88-1.35),p = 0.42)。 结论基于壳聚糖的高血压治疗可降低未控制高血压患者血管并发症的发生率。不过,不建议已控制的高血压患者在 CAG 或 PCI 术后使用壳聚糖 HP 治疗。
{"title":"Chitosan-Based Hemostatic Pad Reduced Vascular Complications After Transradial Coronary Intervention in Uncontrolled Hypertensive Patients: Application of Chitosan-Based Hemostatic Pad on CAG or PCI","authors":"Lu Qian,&nbsp;Ming-Qiang Cao,&nbsp;Ze-Xiong Feng,&nbsp;Cao Zou,&nbsp;Si-Jia Sun,&nbsp;Sheng-Da Hu","doi":"10.1155/2024/4819420","DOIUrl":"https://doi.org/10.1155/2024/4819420","url":null,"abstract":"<div>\u0000 <p><b>Background:</b> Vascular complications after coronary angiography (CAG) or percutaneous coronary intervention (PCI) are a major concern for revascularization therapies. In this study, we investigated whether the application of a chitosan-based hemostatic pad (HP) could ameliorate vascular complications after CAG or PCI procedures.</p>\u0000 <p><b>Methods:</b> We retrospectively analyzed patients undergoing CAG or PCI in our cardiovascular center from January 2019 to December 2021. The incidence of total vascular complications including errhysis, large hematoma, pseudoaneurysm, radial artery occlusion (RAO), blister, and pain was recorded. Subgroup analyses of patients with a history of hypertension, patients with uncontrolled hypertension, and patients with controlled hypertension were performed.</p>\u0000 <p><b>Results:</b> Our results demonstrated that the application of chitosan-based HP had no effect on vascular complications after CAG or PCI procedures (odds ratio [OR]: 1.03 (0.84–1.26), <i>p</i> = 0.80). Nevertheless, chitosan-based HP treatment markedly decreased the incidence of vascular complications in uncontrolled hypertensive patients (OR: 0.32 (0.11–0.95), <i>p</i> = 0.04), but not in hypertensive patients with controlled blood pressure (BP) (OR: 1.09 (0.88–1.35), <i>p</i> = 0.42).</p>\u0000 <p><b>Conclusions:</b> Chitosan-based HP treatment could reduce the incidence of vascular complications in patients with uncontrolled hypertension. Nonetheless, applying chitosan-based HP treatment after CAG or PCI procedures is not recommendable for controlled hypertensive patients.</p>\u0000 </div>","PeriodicalId":16329,"journal":{"name":"Journal of interventional cardiology","volume":"2024 1","pages":""},"PeriodicalIF":1.6,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/4819420","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142244958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Optimizing Cardiac Resynchronization Therapy in Heart Failure Patients With Prolonged QRS Duration: Insights Into Electrical and Mechanical Dyssynchrony 优化 QRS 间期延长的心衰患者的心脏再同步化治疗:对电气和机械不同步的见解
IF 1.6 3区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-09-16 DOI: 10.1155/2024/5549433
Zhisheng Chen, Lois Balmer, Xuerui Tan

Heart failure (HF) represents a critical stage of cardiac disease, associated with high morbidity and mortality. Cardiac resynchronization therapy (CRT) has become a pivotal treatment for HF patients with prolonged QRS duration. This therapy employs a biventricular pacing system to correct cardiac electromechanical dyssynchrony, thereby improving cardiac function, symptoms, and prognosis. Numerous clinical trials have consistently highlighted the benefits of CRT in this subgroup, leading to its unanimous recommendation in clinical practice guidelines. However, a significant proportion of patients do not achieve an adequate therapeutic response, despite adherence to these guidelines. As CRT treats patients by correcting cardiac electromechanical dyssynchrony, assessing electrical and mechanical dyssynchrony is crucial in candidate selection. This review explores the evidence, recent clinical practice guidelines, and insight into electrical and mechanical dyssynchrony to optimize CRT candidate selection in HF patients with prolonged QRS duration.

心力衰竭(HF)是心脏病的一个关键阶段,与高发病率和高死亡率有关。心脏再同步化疗法(CRT)已成为治疗 QRS 间期延长的心力衰竭患者的关键疗法。这种疗法采用双心室起搏系统来纠正心脏机电不同步,从而改善心脏功能、症状和预后。大量临床试验一致强调了 CRT 对这一亚组患者的益处,因此临床实践指南一致推荐使用 CRT。然而,尽管遵循了这些指南,仍有相当一部分患者无法获得充分的治疗反应。由于 CRT 通过纠正心脏机电不同步来治疗患者,因此评估电气和机械不同步对候选者的选择至关重要。本综述探讨了相关证据、最新临床实践指南以及对电气和机械不同步的见解,以优化 QRS 间期延长的 HF 患者的 CRT 候选者选择。
{"title":"Optimizing Cardiac Resynchronization Therapy in Heart Failure Patients With Prolonged QRS Duration: Insights Into Electrical and Mechanical Dyssynchrony","authors":"Zhisheng Chen,&nbsp;Lois Balmer,&nbsp;Xuerui Tan","doi":"10.1155/2024/5549433","DOIUrl":"https://doi.org/10.1155/2024/5549433","url":null,"abstract":"<div>\u0000 <p>Heart failure (HF) represents a critical stage of cardiac disease, associated with high morbidity and mortality. Cardiac resynchronization therapy (CRT) has become a pivotal treatment for HF patients with prolonged QRS duration. This therapy employs a biventricular pacing system to correct cardiac electromechanical dyssynchrony, thereby improving cardiac function, symptoms, and prognosis. Numerous clinical trials have consistently highlighted the benefits of CRT in this subgroup, leading to its unanimous recommendation in clinical practice guidelines. However, a significant proportion of patients do not achieve an adequate therapeutic response, despite adherence to these guidelines. As CRT treats patients by correcting cardiac electromechanical dyssynchrony, assessing electrical and mechanical dyssynchrony is crucial in candidate selection. This review explores the evidence, recent clinical practice guidelines, and insight into electrical and mechanical dyssynchrony to optimize CRT candidate selection in HF patients with prolonged QRS duration.</p>\u0000 </div>","PeriodicalId":16329,"journal":{"name":"Journal of interventional cardiology","volume":"2024 1","pages":""},"PeriodicalIF":1.6,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/5549433","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142244515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-Term Outcome of Left Heart Function after Catheter Ablation in Patients with Persistent Atrial Fibrillation Combined with Preserved Ejection Fraction Heart Failure 持续性心房颤动合并射血分数保留型心力衰竭患者导管消融术后左心功能的长期预后
IF 1.6 3区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-07-25 DOI: 10.1155/2024/8332948
Qian Liu, Yan Zhang, Yanlei Zhao, Ling You, Jinglan Wu, Hongning Yin, Ruiqin Xie

Objective. We aimed to examine the benefits of catheter ablation on left heart structure and function in patients with persistent atrial fibrillation (AF) accompanied by heart failure (HF) with preserved ejection fraction (HFpEF), in comparison with the benefits in patients with AF accompanied by HF with reduced ejection fraction (HFrEF) or patients with no HF. Methods. A total of 399 patients with nonvalvular persistent AF who underwent catheter ablation from 2015 to 2021 were retrospectively included sixty-seven patients with recurrence of AF within 1 year were excluded, as well as 53 patients who failed to be followed up at (12 ± 1) months after the procedure. Finally, 279 patients who fulfilled the criteria were included and divided into these groups: the HFpEF group (left ventricular ejection fraction (LVEF) ≥50% and N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) ≥125 pg/ml or E/e′ ≥15, n = 116), HFrEF group (LVEF <50%, n = 48), and no HF group (NT-proBNP <125 pg/ml, n = 115). The endpoints were changes in image-based functional status from baseline to 1 year, including echocardiogram and speckle-tracking echocardiography. Results. The left atrial structure of patients with HFpEF decreased significantly 1 year after catheter ablation (left atrial anteroposterior dimension: 41.48 ± 4.53 mm vs. 38.64 ± 4.40; left atrial mediolateral dimension: 41.99 ± 5.52 vs. 38.24 ± 4.63 mm; left atrial superoinferior dimension: 61.36 ± 6.73 vs. 56.44 ± 6.97 mm). The left atrial and left ventricular volumes were significantly reduced and the ejection fraction was increased in all three groups, with HFrEF patients benefiting more. In the speckle-tracking echocardiography indexes, significant improvements were observed in left atrial strain (16.83 ± 6.91 vs. 28.05 ± 9.92), left atrial storage function (0.97 ± 0.38 vs. 1.49 ± 0.58), and left atrial pump function (−1.15 ± 0.55 vs. −1.68 ± 0.75) among HFpEF patients after 1 year, with no changes in left atrial conduit function (−1.55 ± 0.62 vs. −1.50 ± 0.54). In addition to the above improvements in left atrial structure and function, there was no significant improvement in left ventricular diastolic function in patients with HFpEF (E/e′, 14.11 ± 5.52 vs. 14.30 ± 7.25, P = 0.85). Conclusion. Catheter ablation is beneficial in restoring sinus rhythm in patients with persistent AF with coexisting HFpEF, significantly decreasing the left atrial size, improving left atrial storage function and left atrial pump function, and increasing left atrial and left ventricular ejection fraction.

目的我们旨在研究导管消融术对射血分数保留型心力衰竭(HF)的持续性房颤(AF)患者左心结构和功能的益处,并与射血分数降低型心力衰竭(HFrEF)的房颤患者或无心力衰竭患者的益处进行比较。研究方法回顾性纳入2015年至2021年期间接受导管消融术的399例非瓣膜性持续性房颤患者,排除了67例1年内房颤复发的患者,以及53例术后(12±1)个月未能随访的患者。最后,279 名符合标准的患者被纳入并分为以下几组:HFpEF 组(左心室射血分数(LVEF)≥50% 和 N 端前脑钠尿肽(NT-proBNP)≥125 pg/ml 或 E/e′≥15, n = 116)、HFrEF 组(LVEF <50%, n = 48)和无 HF 组(NT-proBNP <125 pg/ml, n = 115)。终点是图像功能状态从基线到一年的变化,包括超声心动图和斑点追踪超声心动图。研究结果导管消融术后1年,HFpEF患者的左心房结构明显缩小(左心房前后径:41.48 ± 4.53 mm):41.48 ± 4.53 mm vs. 38.64 ± 4.40;左心房内外侧尺寸:41.99 ± 5.52 mm vs. 38.64 ± 4.40:41.99 ± 5.52 vs. 38.24 ± 4.63 mm;左心房上内侧尺寸:61.36 ± 6.73 vs. 56.44 ± 6.97 mm)。三组患者的左心房和左心室容积均明显缩小,射血分数增加,其中高频率心衰患者获益更多。在斑点追踪超声心动图指标方面,观察到左心房应变(16.83 ± 6.91 vs. 28.05 ± 9.92)、左心房储存功能(0.97 ± 0.38 vs. 1.49 ± 0.58)和左心房泵功能(-1.15 ± 0.55 vs. -1.68 ± 0.75),而左心房导管功能(-1.55 ± 0.62 vs. -1.50 ± 0.54)则没有变化。除了上述左心房结构和功能的改善外,HFpEF 患者的左心室舒张功能也没有明显改善(E/e′,14.11 ± 5.52 vs. 14.30 ± 7.25,P = 0.85)。结论导管消融有利于合并高频低搏动的持续性房颤患者恢复窦性心律,显著缩小左心房面积,改善左心房储存功能和左心房泵功能,提高左心房和左心室射血分数。
{"title":"Long-Term Outcome of Left Heart Function after Catheter Ablation in Patients with Persistent Atrial Fibrillation Combined with Preserved Ejection Fraction Heart Failure","authors":"Qian Liu,&nbsp;Yan Zhang,&nbsp;Yanlei Zhao,&nbsp;Ling You,&nbsp;Jinglan Wu,&nbsp;Hongning Yin,&nbsp;Ruiqin Xie","doi":"10.1155/2024/8332948","DOIUrl":"https://doi.org/10.1155/2024/8332948","url":null,"abstract":"<div>\u0000 <p><i>Objective</i>. We aimed to examine the benefits of catheter ablation on left heart structure and function in patients with persistent atrial fibrillation (AF) accompanied by heart failure (HF) with preserved ejection fraction (HFpEF), in comparison with the benefits in patients with AF accompanied by HF with reduced ejection fraction (HFrEF) or patients with no HF. <i>Methods</i>. A total of 399 patients with nonvalvular persistent AF who underwent catheter ablation from 2015 to 2021 were retrospectively included sixty-seven patients with recurrence of AF within 1 year were excluded, as well as 53 patients who failed to be followed up at (12 ± 1) months after the procedure. Finally, 279 patients who fulfilled the criteria were included and divided into these groups: the HFpEF group (left ventricular ejection fraction (LVEF) ≥50% and N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) ≥125 pg/ml or E/e′ ≥15, <i>n</i> = 116), HFrEF group (LVEF &lt;50%, <i>n</i> = 48), and no HF group (NT-proBNP &lt;125 pg/ml, <i>n</i> = 115). The endpoints were changes in image-based functional status from baseline to 1 year, including echocardiogram and speckle-tracking echocardiography. <i>Results</i>. The left atrial structure of patients with HFpEF decreased significantly 1 year after catheter ablation (left atrial anteroposterior dimension: 41.48 ± 4.53 mm vs. 38.64 ± 4.40; left atrial mediolateral dimension: 41.99 ± 5.52 vs. 38.24 ± 4.63 mm; left atrial superoinferior dimension: 61.36 ± 6.73 vs. 56.44 ± 6.97 mm). The left atrial and left ventricular volumes were significantly reduced and the ejection fraction was increased in all three groups, with HFrEF patients benefiting more. In the speckle-tracking echocardiography indexes, significant improvements were observed in left atrial strain (16.83 ± 6.91 vs. 28.05 ± 9.92), left atrial storage function (0.97 ± 0.38 vs. 1.49 ± 0.58), and left atrial pump function (−1.15 ± 0.55 vs. −1.68 ± 0.75) among HFpEF patients after 1 year, with no changes in left atrial conduit function (−1.55 ± 0.62 vs. −1.50 ± 0.54). In addition to the above improvements in left atrial structure and function, there was no significant improvement in left ventricular diastolic function in patients with HFpEF (E/e′, 14.11 ± 5.52 vs. 14.30 ± 7.25, <i>P</i> = 0.85). <i>Conclusion</i>. Catheter ablation is beneficial in restoring sinus rhythm in patients with persistent AF with coexisting HFpEF, significantly decreasing the left atrial size, improving left atrial storage function and left atrial pump function, and increasing left atrial and left ventricular ejection fraction.</p>\u0000 </div>","PeriodicalId":16329,"journal":{"name":"Journal of interventional cardiology","volume":"2024 1","pages":""},"PeriodicalIF":1.6,"publicationDate":"2024-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/8332948","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141967533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of Different Adjunctive Protective Devices to Reduce Operator Radiation Exposure in Percutaneous Coronary Procedures: The RAPTOR Study 不同辅助保护装置对减少经皮冠状动脉手术中操作者辐射暴露的作用:RAPTOR 研究
IF 1.6 3区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-07-22 DOI: 10.1155/2024/8815778
Alessandro Sciahbasi, Nicolò Salvi, Roberto Patrizi, Cristian Di Russo, Maria Cera, Alessandro Bocci, Francesco Starnazzi, Silvio Fedele, Antonino Granatelli

Objective. To compare the relative effectiveness of different anti-Rx devices in terms of radiation dose absorbed by operators during percutaneous coronary procedures (diagnostic or interventional). Background. Direct comparisons among different adjunctive anti-Rx devices during percutaneous coronary procedures to reduce operator radiation exposure are lacking. Methods. We retrospectively analyzed the last 200 percutaneous procedures performed by a single operator according to the use of adjunctive protective devices (group 1) or standard anti-Rx setting (group 2). Subsequently, the procedures in group 1 have been divided according to the protective device utilized (homemade pelvic drape with under-table curtain, or RADPAD drape, or the STAR System device, or the Rampart shield). The primary endpoint was the operator radiation dose at the thorax. Results. Groups 1 and 2 did not show significant differences in terms of anthropometric data or cardiovascular risk factors. The use of adjunctive anti-Rx devices was associated with a significant reduction in operator radiation exposure compared to standard radioprotection (12.8 μSv [7–21] and 22.6 μSv [11–36], respectively; p < 0.0001). Globally, the anti-Rx devices utilized were associated with a reduced operator radiation exposure (11.7 μSv [2–19] for homemade drapes, 13.5 μSv [9–29] for RADPAD drape, 15 μSv [11–30] for STAR Board System, and 8 μSv [5–19] for Rampart; p < 0.0001) with the homemade drapes and the Rampart system showing a lower operator exposure. Conclusions. The use of anti-Rx devices during percutaneous coronary procedures is associated with a significant lower operator radiation exposure with the greater effect obtained with pelvic drapes and the Rampart system.

目的就经皮冠状动脉手术(诊断性或介入性)中操作人员吸收的辐射剂量而言,比较不同抗 Rx 装置的相对有效性。背景。在经皮冠状动脉手术过程中,缺乏对不同辅助抗辐射装置进行直接比较,以减少操作者的辐射暴露。方法。我们根据辅助保护装置(第 1 组)或标准抗辐射装置(第 2 组)的使用情况,回顾性分析了由单个操作者完成的最近 200 例经皮手术。随后,根据所使用的保护装置(带台下帘的自制骨盆帘,或 RADPAD 帘,或 STAR 系统装置,或 Rampart 防护罩)对第 1 组的手术进行了划分。主要终点是操作者胸部的辐射剂量。结果第一组和第二组在人体测量数据或心血管风险因素方面没有明显差异。与标准辐射防护相比,使用辅助抗辐射装置可显著降低操作者的辐射量(分别为 12.8 μSv [7-21] 和 22.6 μSv [11-36]; p < 0.0001)。在全球范围内,所使用的抗反转录装置与操作者辐射暴露量的减少有关(自制帘布为 11.7 μSv [2-19],RADPAD 帘布为 13.5 μSv [9-29],STAR 板系统为 15 μSv [11-30],Rampart 为 8 μSv [5-19];p <;0.0001),其中自制帘布和 Rampart 系统显示出较低的操作者暴露量。结论。在经皮冠状动脉手术中使用抗反转录装置可显著降低操作者的辐射暴露,其中骨盆垂帘和 Rampart 系统的效果更好。
{"title":"Role of Different Adjunctive Protective Devices to Reduce Operator Radiation Exposure in Percutaneous Coronary Procedures: The RAPTOR Study","authors":"Alessandro Sciahbasi,&nbsp;Nicolò Salvi,&nbsp;Roberto Patrizi,&nbsp;Cristian Di Russo,&nbsp;Maria Cera,&nbsp;Alessandro Bocci,&nbsp;Francesco Starnazzi,&nbsp;Silvio Fedele,&nbsp;Antonino Granatelli","doi":"10.1155/2024/8815778","DOIUrl":"https://doi.org/10.1155/2024/8815778","url":null,"abstract":"<div>\u0000 <p><i>Objective</i>. To compare the relative effectiveness of different anti-Rx devices in terms of radiation dose absorbed by operators during percutaneous coronary procedures (diagnostic or interventional). <i>Background</i>. Direct comparisons among different adjunctive anti-Rx devices during percutaneous coronary procedures to reduce operator radiation exposure are lacking. <i>Methods</i>. We retrospectively analyzed the last 200 percutaneous procedures performed by a single operator according to the use of adjunctive protective devices (group 1) or standard anti-Rx setting (group 2). Subsequently, the procedures in group 1 have been divided according to the protective device utilized (homemade pelvic drape with under-table curtain, or RADPAD drape, or the STAR System device, or the Rampart shield). The primary endpoint was the operator radiation dose at the thorax. <i>Results</i>. Groups 1 and 2 did not show significant differences in terms of anthropometric data or cardiovascular risk factors. The use of adjunctive anti-Rx devices was associated with a significant reduction in operator radiation exposure compared to standard radioprotection (12.8 <i>μ</i>Sv [7–21] and 22.6 <i>μ</i>Sv [11–36], respectively; <i>p</i> &lt; 0.0001). Globally, the anti-Rx devices utilized were associated with a reduced operator radiation exposure (11.7 <i>μ</i>Sv [2–19] for homemade drapes, 13.5 <i>μ</i>Sv [9–29] for RADPAD drape, 15 <i>μ</i>Sv [11–30] for STAR Board System, and 8 <i>μ</i>Sv [5–19] for Rampart; <i>p</i> &lt; 0.0001) with the homemade drapes and the Rampart system showing a lower operator exposure. <i>Conclusions</i>. The use of anti-Rx devices during percutaneous coronary procedures is associated with a significant lower operator radiation exposure with the greater effect obtained with pelvic drapes and the Rampart system.</p>\u0000 </div>","PeriodicalId":16329,"journal":{"name":"Journal of interventional cardiology","volume":"2024 1","pages":""},"PeriodicalIF":1.6,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/8815778","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141968054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of interventional cardiology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1